New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
07:31 EDTTXMDTherapeuticsMD receives notice of allowance for patent
TherapeuticsMD received a Notice of Allowance from the U.S. Patent and Trademark Office pertaining to its U.S. Patent Application 13/684,002 - "Natural Combination Hormone Replacement Formulations and Therapies." This Patent Application covers the company’s platform technology TX 12-001-HR, its oral bioidentical 17β-estradiol and progesterone combination drug candidate. Robert Finizio, CEO and Co-founder of TherapeuticsMD, says "Based on clinical data presented earlier this year, we believe TX 12-001-HR has overcome these hurdles and that this novel combination of 17ß- estradiol and progesterone may achieve equivalent efficacy with better bioavailability as compared to current hormone therapies. We eagerly await the outcomes of the ongoing REPLENISH Trial."
News For TXMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 18, 2015
08:03 EDTTXMDTherapeuticsMD names Angus Russell, J. Martin Carroll as directors
TherapeuticsMD (TXMD) announced the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors. Angus C. Russell served as CEO of Shire PLC (SHPG) from June 2008 until April 2013. J. Martin Carroll served as president and CEO of Boehringer Ingelheim Corp. U.S. from 2003 until 2011.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use